To the full analysis
City Therapeutics Stock: Valuation and P/E
CTYHere you can see what City Therapeutics Inc. costs today relative to earnings, sales and book value, and how that compares with its own valuation history. A high P/E is not a verdict by itself; what matters is whether it sits above or below what the market usually grants this company.
Daily figure as of 20 Nov 2026
P/E
no data
P/S
0.2
P/B
no data
PEG
no data
Against Its Own Valuation History
Each fiscal year is shown with its P/E on the year-end date, using the price at the time.
There is no reliable data on this for this company.
Data and Required Disclosures
- ; time horizon around 12 months
- Rated Neutral since 7 Nov 2026
- Price: closing price of 19 Nov 2026
- Data from Financial Modeling Prep (FMP) based on the company's reports, latest fiscal year 2019. MEQIRI calculates the score and fair value itself every night.
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
